Activin E

Overview

1. Activin E, also known as Inhibin Beta E (INHBE), is a member of the Transforming Growth Factor-beta (TGF-β) superfamily and functions as a key hepatokine involved in metabolic regulation, cell differentiation, tissue repair, and reproductive function.
2. It acts as a cytokine produced primarily by the liver, with minor secretion from adipose tissue, skeletal muscle, and placenta. It interacts with receptors such as Activin Receptor IIA/IIB and signals through ALK4 and ALK7-SMAD pathways, influencing gene expression and energy homeostasis.
3. As a multifunctional protein, it is implicated in glucose and lipid metabolism, insulin sensitivity, obesity, Non-Alcoholic Fatty Liver Disease (NAFLD), and fibrosis.
4. It functions as both an endocrine and paracrine regulator, facilitating liver–adipose communication, maintaining metabolic balance, and protecting the liver from steatosis by limiting fat influx.
5. The Activin E assay measures its circulating levels to assess metabolic and reproductive health, serving as a biomarker and potential therapeutic target for conditions such as diabetes, metabolic syndrome, and cancer.

Symptoms

(Clinical manifestations that warrant Activin E evaluation)

1. Unexplained obesity or excessive abdominal fat accumulation, suggesting altered hepatokine signaling.
2. Insulin resistance or elevated blood glucose indicates disrupted glucose metabolism.
3. Fatty liver symptoms, including liver enlargement or abnormal liver enzyme levels, suggest NAFLD or NASH.
4. Menstrual irregularities or infertility in females due to reproductive hormone imbalance.
5. Fatigue, weakness, or muscle wasting are often associated with metabolic dysregulation or cachexia.
6. Inflammatory symptoms, such as joint pain and swelling, possibly linked to autoimmune or metabolic inflammation.
7. Signs of cancer progression, including unexplained weight loss, organ enlargement, or persistent inflammation in tissues affected by ovarian, breast, or colorectal cancer.
8. Liver fibrosis or hepatic steatosis is indicated by elevated Activin E levels in blood tests.

Causes

(Factors leading to elevated or dysregulated Activin E)

1. Metabolic disorders, including obesity, insulin resistance, and Type 2 diabetes, often result in increased Activin E production.
2. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) are strongly correlated with elevated Activin E levels (>150 pg/mL).
3. Chronic inflammation, which stimulates cytokine signaling and hepatic production of Activin E.
4. Cancers, such as ovarian, breast, and prostate malignancies, in which Activin E promotes tumor proliferation, invasion, and metastasis.
5. Reproductive disorders, including Polycystic Ovary Syndrome (PCOS) and Hypogonadotropic Hypogonadism, are caused by an imbalance in activin signaling.
6. Liver injury or fibrosis, where increased Activin E acts as a compensatory hepatokine for regeneration and tissue repair.
7. Experimental conditions involving muscle wasting or cachexia, showing elevated Activin E in systemic circulation.
8. Genetic variations in the INHBE gene, which can alter metabolic efficiency and adipose tissue regulation.

Risk Factors

(Populations at greater risk for altered Activin E activity)

1. Obese individuals and those with metabolic syndrome are prone to elevated Activin E and insulin resistance.
2. Patients with chronic liver disease, including NAFLD, NASH, or fibrosis, exhibit higher Activin E levels.
3. Individuals with Type 2 diabetes have impaired glucose metabolism and increased hepatic secretion.
4. Cancer patients, especially those with ovarian, colorectal, or prostate cancer, may benefit from Activin E, which supports tumor progression.
5. Women with reproductive dysfunction, such as PCOS or ovulatory disorders, show altered Activin E signaling.
6. Patients undergoing chemotherapy, where these monitoring aids in treatment evaluation.
7. Elderly and sedentary individuals with greater risk of insulin resistance and hepatic lipid accumulation.
8. Genetic predisposition, where INHBE polymorphisms influence lipid storage and diabetes susceptibility.

Prevention

(Measures to manage, monitor, and interpret Activin E effectively)

1. Laboratory testing:
   1. Collect 3 mL of blood in either plain red-capped tubes (serum)or lavender-capped EDTA tubes (plasma).
   2. Separate serum/plasma immediately and send to the lab for analysis.
   3. Alternative sources include cell culture supernatants or tissue homogenates prepared in PBS (pH 7.4).
2. Analytical methods:
   1. Common estimation techniques include Sandwich ELISA (sELISA), Radioimmunoassay (RIA), and Quantitative Chemiluminescent Immunoassay (CLIA).
3. Reference range:
   1. Healthy adults: 50–150 pg/mL
   2. NAFLD/NASH patients: >150 pg/mL (elevated)
   3. Obese individuals: Variable but generally higher than normal
4. Preventive strategies:
   1. Maintain a healthy body weight through diet and exercise to regulate hepatokine activity.
   2. Monitor liver function regularly in individuals with obesity or metabolic disease.
   3. Screen for reproductive health in women with PCOS or infertility issues.
   4. Integrate clinical findings with its results to avoid false positives or negatives, as test specificity may vary.
5. Therapeutic implications:
   1. Activin E modulation offers potential in metabolic syndrome therapy, Type 2 diabetes control, anti-fibrotic treatments, muscle wasting prevention, and liver regeneration enhancement.
   2. Continuous clinical correlation and follow-up ensure accurate interpretation and safe therapeutic outcomes.